Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluralaner
- Development stage
- Phase 4
- Lead developer
- Intervet
- Modality
- Small Molecules
- Administration
- Oral, Topical
01
Overview
Fluralaner is a systemic insecticide and acaricide belonging to the isoxazoline class. It is primarily used in veterinary medicine for the treatment and prevention of flea and tick infestations in dogs and cats. Fluralaner acts as an inhibitor of the arthropod nervous system by antagonizing ligand-gated chloride channels—specifically gamma-aminobutyric acid (GABA) receptors and glutamate receptors—leading to paralysis and death of target parasites. The drug exhibits high selectivity for arthropod neurons over mammalian neurons, contributing to its safety profile in companion animals. Fluralaner was developed by MSD Animal Health (a division of Merck & Co.) and is marketed under several brand names including Bravecto (for dogs and cats), Exzolt (for poultry), Bravecto Plus (combination with moxidectin for cats), and Bravecto 1-Month (shorter duration formulation). It has been approved for use in multiple regions including the US, EU, Australia, and others[1][2][3][4][5][8].
- Brand names
- BravectoExzoltBravecto PlusBravecto 1-MonthBravecto1-MonthBravecto-1-Month
02
Targets
GluCl (Glutamate-gated chloride channel)
Beyond the preview
Go deeper on fluralaner.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluralaner.